A Non-Randomized Multicentre Trial of Human Immune Plasma for Treatment of Hantavirus Cardiopulmonary Syndrome Caused by Andes Virus
Antiviral Therapy · 2015-05 · 20 (4) · 377-386
DOI: 10.3851/imp2875 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Antiviral Therapy, online erschienen am 01.05.2014. Verfasst von Pablo A Vial und 20 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile. pvial@udd.cl. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Background
In Chile, Andes virus (ANDV) is the sole aetiological agent of hantavirus cardiopulmonary syndrome (HCPS) with mean annual incidence of 55 cases, 32% case fatality rate (CFR) and no specific treatment. Neutralizing antibody (NAb) titres at hospital admission correlate inversely with HCPS severity. We designed an open trial to explore safety and efficacy and evaluate pharmacokinetics of immune plasma as a treatment strategy for this disease.
Methods
We performed plasmapheresis on donors at least 6 months after HCPS and measured NAb titres through a focus-reduction neutralization test. Subjects admitted to 10 study sites with suspected/confirmed HCPS were eligible for treatment with immune plasma by intravenous infusion at an ANDV NAb dose of 5,000 U/kg. HCPS was confirmed through immunoglobulin M serology or reverse transcriptase-PCR. The main outcome was mortality within 30 days.
Results
From 2008–2012, we enrolled and treated 32 cases and confirmed HCPS in 29. CFR of hantavirus plasma-treated cases was 4/29 (14%); CFR of non-treated cases in the same period in Chile was 63/199 (32%; P=0.049, OR=0.35, CI=0.12, 0.99); CFR of non-treated cases at the same study sites between 2005–2012 was 18/66 (27%; ( P=0.15, OR=0.43, CI=0.14, 1.34) and CFR in a previous methylprednisolone treatment study was 20/60 (33%; P=0.052, OR=0.32, CI=0.10, 1.00). We detected no serious adverse events associated to plasma infusion. Plasma NAb titres reached in recipients were variable and viral load remained stable.
Conclusions
Human ANDV immune plasma infusion appears safe for HCPS. We observed a decrease in CFR in treated cases with borderline significance that will require further studies for confirmation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile. pvial@udd.cl.
Förderung
- NIAID NIH HHS
Zitieren
APA
Vial, P. A., Valdivieso, F., Calvo, M., Rioseco, M. L., Riquelme, R., Araneda, A., Tomicic, V., Graf, J., Paredes, L., Florenzano, M., Bidart, T., Cuiza, A., Marco, C., Hjelle, B., Ye, C., Hanfelt-Goade, D., Vial, C., Rivera, J. C., Delgado, I., …, & Hantavirus Study Group in Chile (2015). A Non-Randomized Multicentre Trial of Human Immune Plasma for Treatment of Hantavirus Cardiopulmonary Syndrome Caused by Andes Virus. Antiviral Therapy, 20(4), 377-386. https://doi.org/10.3851/imp2875
Vancouver
Vial PA, Valdivieso F, Calvo M, Rioseco ML, Riquelme R, Araneda A, et al. A Non-Randomized Multicentre Trial of Human Immune Plasma for Treatment of Hantavirus Cardiopulmonary Syndrome Caused by Andes Virus. Antiviral Therapy. 2015;20(4):377-386. doi:10.3851/imp2875
BibTeX
@article{Vial2015,
author = {Vial, Pablo A and Valdivieso, Francisca and Calvo, Mario and Rioseco, M Luisa and Riquelme, Raul and Araneda, Andres and Tomicic, Vinko and Graf, Jerónimo and Paredes, Laura and Florenzano, Matias and Bidart, Teresa and Cuiza, Analia and Marco, Claudia and Hjelle, Brian and Ye, Chunyan and Hanfelt-Goade, Diane and Vial, Cecilia and Rivera, Juan C and Delgado, Iris and Mertz, Gregory J and Hantavirus Study Group in Chile, Hantavirus Study Group in Chile},
title = {A Non-Randomized Multicentre Trial of Human Immune Plasma for Treatment of Hantavirus Cardiopulmonary Syndrome Caused by Andes Virus},
journal = {Antiviral Therapy},
year = {2015},
volume = {20},
number = {4},
pages = {377--386},
doi = {10.3851/imp2875}
}
EUVIMED